Related Experiment Video

Updated: Aug 11, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Stroke prevention: anti-platelet and anti-thrombolytic therapy

H C Diener1

  • 1Professor, Department of Neurology, University of Essen, Germany. h.diener@uni-essen.de

Neurologic Clinics
|April 11, 2000
PubMed

Insights

Antiplatelet drugs reduce stroke risk in TIA and noncardiac ischemic stroke patients. Aspirin plus dipyridamole or clopidogrel offer better prevention than aspirin alone, with improved safety profiles.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Transient ischemic attack (TIA) and ischemic stroke necessitate effective preventative strategies.
  • Antiplatelet therapy is a cornerstone in managing noncardiac ischemic stroke and TIA.
  • Understanding the comparative efficacy and safety of different antiplatelet agents is crucial.

Purpose of the Study:

  • To evaluate the efficacy of antiplatelet drugs in reducing stroke risk in patients with TIA or noncardiac ischemic stroke.
  • To compare the effectiveness and safety profiles of various antiplatelet agents, including aspirin, aspirin with dipyridamole, ticlopidine, and clopidogrel.
  • To assess the role and safety of anticoagulation in this patient population.

Main Methods:

  • Review of clinical trial data on antiplatelet drug efficacy and safety.
  • Comparison of stroke risk reduction percentages for different therapeutic regimens.
  • Analysis of adverse event profiles, including bleeding complications and specific side effects like neutropenia.

Main Results:

  • Antiplatelet drugs decrease stroke risk by 11-15% and stroke, myocardial infarction (MI), and vascular death by 15-22%, without impacting overall mortality.
  • Low-dose aspirin (50-325 mg) is as effective as higher doses with fewer gastrointestinal side effects; severe bleeding is not dose-dependent.
  • Aspirin combined with slow-release dipyridamole is superior to aspirin alone; clopidogrel offers a better safety profile than ticlopidine.
  • High-intensity anticoagulation (INR 3.0-4.5) is associated with excessive danger; the safety and efficacy of lower-intensity anticoagulation remain undetermined.

Conclusions:

  • Antiplatelet therapy is effective in preventing recurrent vascular events in TIA and noncardiac ischemic stroke patients.
  • Combination therapy (aspirin/dipyridamole) and newer agents like clopidogrel represent advancements in stroke prevention due to improved efficacy and safety.
  • Current anticoagulation strategies at higher intensities are not recommended; further research is needed for lower-intensity regimens.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...